Article Search

Talquetamab plus daratumumab (with or without pomalidomide) delivered a striking progression-free survival (PFS) benefit over daratumumab plus pomalidomide and dexamethasone (DPd) in early-line relapsed/refractory myeloma, 24-month PFS of ~80% versus 51% and MRD-negative CR rates three times higher than the control arm. OS trending favorably but not yet mature. The GPRC5D toxicity profile is manageable but distinct, counsel patients upfront on taste changes, skin/nail effects, weight loss, and watch closely for ataxia/balance issues, which warrant holding the drug and early neurology involvement.

Quadruplet induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa‑KRd) has reset expectations for transplant‑eligible NDMM and enables measurable residual disease (MRD)‑adapted strategies; MRD‑negativity at 10^-5 is strongly prognostic, and the necessity of autologous stem-cell transplantation (ASCT)—particularly tandem ASCT—amid deep responses is being re‑examined. Practically, MRD‑adapted consolidation after Isa‑KRd suggests no added depth from ASCT in MRD patients and no advantage for tandem ASCT over single ASCT + Isa‑KRd in MRD+ patients. So in day‑to‑day practice, this looks like a chance to de‑escalate transplant intensity while awaiting mature progression-free survival (PFS)/overall survival (OS) data.